Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study

Table 5 Change from baseline in DAS28-ESR results (full analysis set)

	Month	csDMARDs plus denosumab (N = 21)		csDMARD therapy alone (N = 22)		Difference (csDMARDs plus denosumab − csDMARD therapy alone)
	Month	N	Adjusted mean [95% CI]	N	Adjusted mean [95% CI]	Adjusted mean [95% CI] P value
DAS28-ESR	6	21	− 0.56 [− 1.08, − 0.05]	21	− 0.54 [− 1.08, − 0.01]	− 0.02 [− 0.60, 0.56] P = 0.9470
DAS28-ESR	12	19	− 0.79 [− 1.32, − 0.26]	21	− 0.31 [− 0.84, 0.23]	− 0.48 [− 1.07, 0.11] P = 0.1087

Data are shown as adjusted mean [95% CI] unless otherwise indicated
N is the number of patients with available data
For adjusted mean, a linear mixed effect model analysis was performed using treatment group, sex, anti-CCP antibody (positive vs negative), baseline DAS28-ESR, measurement time point, and the interaction between the treatment group and measurement time point as fixed effects; patients as random effects; and baseline values as covariates
CCP cyclic citrullinated peptide, CI confidence interval, csDMARD conventional synthetic disease-modifying anti-rheumatic drug, DAS28-ESR Disease Activity Score in 28 joints for rheumatoid arthritis with erythrocyte sedimentation rate

ISSN: 1478-6362